Novartis Venture Funds, the $750m corporate venturing division of pharmaceutical firm Novartis, has participated in a series B round of funding for Swiss-based biopharmaceutical company Covagen AG, which develops protein-based therapeutics for the treatment of inflammatory diseases and cancer. Covagen closed Its tranched B round of funding at CHF 42m ($46.9m) with the option to extend the round with an additional CHF 14m ( $15.6m), which would bring the total round to CHF 56m ( $62.6).
Investment company Gimv led…
